Primary Axillary Hyperhidrosis Treatment

primary axillary hyperhidrosis treatment

Retrodermal curettage

A retrodermal curettage is one option for treating primary axillary hyperhidrosis. It involves removing sweat glands with a special instrument called a curette. The patient is given a local anaesthetic to make the procedure less painful. The surgeon will then use suction to remove the glands. This treatment is effective in eliminating excessive sweating and can improve a patient’s quality of life.

Retrodermal curettage is a minimally invasive surgical procedure for primary axillary hyperhidrosic patients. The procedure involves removing the affected sweat glands and deep dermal cellular tissue. This minimally invasive treatment is often performed in an outpatient setting under tumescent anesthesia. It is safe for patients and has very low recurrence rates.

The surgery is typically a modified Skoog procedure. The patient is given a padded surgical bandage to cover the dissected area. The distal part of the bandage is attached to the arm, while the proximal end is attached to the chest. The skin is then sutured closed using inverted deep dermal absorbable sutures. The surgeon should place a drain through a small incision, as hematoma can form if there is no drain.

Patients with primary axillary hyperhidrosis should be evaluated for secondary causes such as systemic disease, drug reactions, and psychiatric problems. Symptoms usually subside with time, but in older patients, the condition is more severe, and it may be indicative of a secondary cause.

During the procedure, the radial skin tension is vital, and the amount of force used during the scraping movements is critical in determining when to stop. Bechara et al. (2007) provide clinical clues to determine if the curettage has achieved adequate results.

This innovative treatment option for primary axillary hyperhidrosises has recently been approved by the United States Food and Drug Administration. Its safety and effectiveness have been demonstrated in two double-blind phase III trials. Moreover, the technique is not invasive.

Retrodermal curettage for primary axellary hyperhidrosis treatment may be an alternative to botulinum toxin A, but is associated with a higher risk of adverse effects. Consequently, curettage may be used in a variety of settings in addition to BTX treatment.

There have been a number of studies performed on the efficacy of retrodermal curettage for treating primary axillary hyperhidrosis. However, results varied widely depending on the intervention and the methods of outcome assessment. Moreover, most studies were small, included fewer than 50 patients, and were poorly reported.

Retrodermal curettage has shown positive results in a limited number of patients. It has been shown to be effective in removing sweat glands that are located in the deep dermis. Besides, it also removes fat from the subcutaneous area and reduces sweating in the area. The benefits of this treatment are long lasting and increase with repeated treatments.

Another option is to use a long-pulsed 800-nm diode laser for the treatment of axillary hyperhidrosis. This treatment can help to eliminate underlying causes of axillary hyperhidrosis and improve the patient’s quality of life.

Fractional radiofrequency microneedling

Radiofrequency microneedling is a treatment that utilizes flow needle technology to deliver controlled amounts of radiofrequency energy deep beneath the skin’s surface. This type of treatment is safe and effective, and does not cause pigmentary changes. It is FDA-cleared for both facial wrinkles and primary axillary hyperhidrosis. Prior studies of this procedure focused on patients of phototypes I-III, but it is effective for patients of all skin colors.

Fractional radiofrequency microneedling is a minimally invasive procedure that requires local anesthesia and a 20-minute treatment. The treatment involves pressing the square tip of the needle into the skin. The energy applied disables sweat glands and reduces sweating. In some patients, up to three sessions are required to achieve permanent results, but others will see improvement after a single session.

High-intensity focused fractional radiofrequency microneedling has been shown to effectively treat primary axillary hyperhidrosis and is safe and well-tolerated. Fractional radiofrequency microneedling is also safe and effective for facial wrinkles. Its insulating design helps control the amount of energy delivered deep within the skin.

While the procedure is relatively safe and effective for the treatment of primary axillary hyperhidrosis, it should be done with caution. The treatment should be repeated every year or so. If the patient is overweight or has a high BMI, the results may not last for a very long time.

One of the most widely studied non-surgical options for hyperhidrosis is botulinum toxin A therapy. Several clinical trials have been conducted to compare the efficacy of existing products and to study new therapies.

Other methods of treatment include underarm surgery, which involves reducing sweat glands. While this procedure is relatively limited in its invasiveness, it does have a significant risk of scarring and nerve damage. Additionally, it is only appropriate for patients with primary axillary hyperhidrosis.

The first step in treating primary axillary hyperhidrosis is a thorough evaluation of the patient’s condition. The doctor should rule out other possible diseases before recommending a specific treatment. In addition, he should check the patient’s thyroid function and metabolic panel. A urine test that measures 5-hydroxyndolacetic acid (TEWameter) will be necessary to determine if there are any complications.


Botox is a popular treatment for axillary hyperhidrosis, which causes excessive sweating. This nonsurgical procedure is safe and has few side effects. Patients often experience a seventy to ninety percent reduction in sweating. This treatment was tested in a study of 300 patients, and results showed immediate improvements. Furthermore, it requires less surgery than other forms of treatment.

Botulinum toxin type A is a neuromodulator that blocks the release of acetylcholine from the postganglionic sympathetic fibers of the sweat gland. Symptomatic patients have reported an anhidrosis response after intracutaneous injections of Botox. In some cases, the response can last for up to a year, but then it reverts.

The average reduction in underarm sweating with Botox treatment is eighty to seventy percent. The results begin to appear within two to four days. In most cases, patients tolerate the treatment well. A topical anesthetic can be applied to help patients feel comfortable during the procedure. The treatment is generally covered by insurance.

Axillary hyperhidrosis can be classified into two types: primary hyperhidrosis and secondary hyperhidrosis. The former is a genetic condition, while the latter is caused by a disease or other cause. Treatment options for both types are available.

The treatment of primary axillary hyperhidrosis with botulinum toxin type A is safe and effective. It has been studied in two-arm double-blind trials. Patients received either 200 or 100 U of botulinum toxin in each axilla. Despite the risks of this procedure, patient satisfaction was very high.

The study used a prospective questionnaire to measure clinical outcomes. The test consisted of 40 healthy volunteers. The results showed that the 3 treatment groups showed statistically significant improvements in hyperhidrosis scores. However, the Glycoprrolate group had a smaller improvement than the BTX-A group. Furthermore, the no-treatment group saw no change.

While Botox is a popular treatment for primary axillary hyperhidros, it should be used only when other forms of treatment have failed. The International Hyperhydrosis Society’s 2008 guidelines for the treatment of axillary hyperhidrosis do not recommend this procedure for all patients, and should only be considered as a last-resort treatment. In addition, patients must be informed and be willing to accept the risks of surgery.

Although there are no clinical trials yet, the treatment may be beneficial for a large number of patients. Moreover, it may help to avoid invasive procedures, including open surgery. The procedure involves a specialized surgeon and may be performed by a dermatologist. The procedure also involves a risk of recurrence.